Colorescience®, a leading dermatologist-recommended specialty skincare and cosmetics company, is pleased to announce an expansion of its best-selling Even Up® line of hyperpigmentation products. New Even Up® Multi-Correction Serum ($89) features patented, clinically-proven Lumira® brightening complex to minimize the appearance of discoloration. The addition of a novel peptide and lipid blend and powerful hydrating ingredients result in …
Interpace Biosciences, Inc. (“Interpace” or “the Company”), today announced that Blue Cross Blue Shield of Illinois, owned by Health Care Services Corporation (HCSC) and the largest health plan in Illinois with greater than 8 million covered lives, has entered into an agreement to provide both coverage and in-network status for Interpace’s molecular combination thyroid tests, …
Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the requirements for trading of the Company’s common stock on the OTCQX® Best Market (“OTCQX”) and will begin trading on OTCQX at the open of the market on February …
Restorative Therapies, Inc – the leading provider of innovative, integrated therapeutic medical devices that are the standard of care in rehabilitation therapy for many neurological conditions – announced today the launch of Xcite2. Xcite2 was designed to allow clinicians to easily and efficiently apply multi-channel FES with task specific activities commonly completed in therapy. The device …
Verogen Inc. announced today that it is expanding capabilities for the NDIS-approved MiSeq FGx Sequencing System with the commercial launch of the ForenSeq Kintelligence Kit, a solution optimized for low input and degraded samples. The kit targets 10,230 forensically curated SNPs, alleviating genetic privacy concerns by minimizing medically informative markers. The seamless integration of this workflow …
reenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) announced today that Mr. Stephan Roker has provided notice of his intention to resign as a director of the Company, effective today, citing the existence of previously unforeseen conflicts of interest as the reason for his resignation.
Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) is pleased to announce that its shareholders have approved a special resolution for an amendment to the Company’s articles and has authorized a consolidation (the “Share Consolidation”) of the Company’s outstanding common shares (“Common Shares”). The resolution was approved at the special meeting of shareholders held …
Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, announced today that it and its subsidiaries have entered into a credit and security agreement for a US$30 million secured credit facility (the “Credit Facility”) with Oxford Finance LLC (“Oxford”).
Onkos Surgical, Inc., an innovator in the field of musculoskeletal oncology and personalized orthopaedics, continues to deliver on its promise of commercializing innovative solutions with the launch of the new ELEOS Proximal Tibia with BioGrip technology. The product, used in complex tumor and orthopaedic reconstructive procedures, is the first FDA cleared, 3D printed limb salvage …
Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that the second largest U.S. Commercial payer will now cover TheraSkin for all lower extremity dermal wounds. TheraSkin is a proven cellular and tissue-based treatment for difficult to heal chronic wounds.
Aktana, the pioneer in AI-driven intelligent engagement for the life sciences industry, announced major milestones of 2020, including key executive hires, expanded customer partnerships, and the launch of its next-generation Contextual Intelligence Engine. Aktana’s growth reflects increasing demand for AI capabilities to enable more effective multichannel customer engagement in life sciences, as evidenced by their nearly …
Innovative Health, Inc. today announced it has received the first-ever U.S. patent for a microlumen reprocessing technology, a milestone in ensuring patient safety while advancing the vital discipline of reprocessing single-use cardiology medical devices. The patent (US Patent 10,830,682), which covers a novel test method for identifying subvisible occluding particles in microlumens, grants Innovative Health a …